The Therapeutic Landscape in Chronic Cough.

Authors:
Smith JA.

Journal:
Lung

Publication Year: 2023

DOI:
10.1007/s00408-023-00666-y

PMCID:
PMC10896934

PMID:
38127133

Journal Information

Full Title: Lung

Abbreviation: Lung

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pulmonary Medicine

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Conflict of interestJAS has received consultancy fees from Axalbion, Algernon, AstraZeneca, Bayer, Bellus Health, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Merck, Nocion Therapeutics, Shionogi, and Trevi Therapeutics. The VitaloJAK algorithm has been licenced by Manchester University Foundation Trust (MFT) and the University of Manchester to Vitalograph Ltd and Vitalograph Ireland. MFT receives royalties which may be shared with the clinical division in which JAS works. Conflict of interest JAS has received consultancy fees from Axalbion, Algernon, AstraZeneca, Bayer, Bellus Health, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Merck, Nocion Therapeutics, Shionogi, and Trevi Therapeutics. The VitaloJAK algorithm has been licenced by Manchester University Foundation Trust (MFT) and the University of Manchester to Vitalograph Ltd and Vitalograph Ireland. MFT receives royalties which may be shared with the clinical division in which JAS works."

Evidence found in paper:

"Funding JAS is funded by the NIHR Manchester Biomedical Research Centre and a Wellcome Investigator Award."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025